The study was designed prior to the extensive use of rituximab in AAV and the sequential use of anti-TNF therapy in BD, and as a result, the pool of patients with refractory vasculitis who were potentially eligible to enter this trial was smaller than anticipated. Here, TNF is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.